Compare PayPal Holdings, Inc. (PYPL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PayPal Holdings, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? PayPal Holdings, Inc. trades at $55.83 (market cap $47.99B), while Spyre Therapeutics Inc. Common Stock trades at $79.73 (market cap $7.35B). The key difference: PayPal Holdings, Inc. is far larger — about 6.5× Spyre Therapeutics Inc. Common Stock's market cap, and PayPal Holdings, Inc. pays a 1% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold PayPal Holdings, Inc. for 106 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PYPL | SYRE | |
|---|---|---|
Market Cap | $47.99B | $7.35B |
Volume | 9,873,263 | 1,624,631 |
Sector | Financials | Health |
52-Week High | $73.01 | $108.92 |
52-Week Low | $39.08 | $22.18 |
Typical Hold Time | 106 Days | 0 Days |
Enterprise Value | $50.14B | $6.35B |
Dividend Yield | 1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PayPal (PYPL) trades at $56.17, up 0.21% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $56.41. The company reported revenue of $33.17B in 2025, with net income of $5.23B and strong profitability metrics, including a 14.36% net margin. Recent news highlights a partnership with Meta's Muse AI agent, potentially boosting checkout capabilities.
PYPL presents a value opportunity with a low P/E of 10.6 and solid cash flow, but faces risks from competitive pressures in digital payments and investor skepticism reflected in a majority hold rating. Upside depends on successful execution of new initiatives under CEO Enrique Lores.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
